2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1557 Surovatamig, a novel, fully human, IgG4, CD19xCD3 bispecific T-cell engager (TCE), is well tolerated and shows efficacy in adolescent and adult patients (pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated results from the phase 1/2 SYRUS study

Ibrahim Aldoss, MD, Gautam Borthakur, MD2, Pere Barba, MD, PhD3, Bijal Shah, MD, MS4, Noah Merin, MD, PhD5, Prof. Dr. Max Topp, MD6, Franco Locatelli, MD PhD7, Jae-Ho Yoon, MD, PhD8, Nuria Martinez-Cibrian, MD9, Guru Subramanian Guru Murthy, MD10, Anna Castleton, MBBS, PhD11, Bela Patel, MD FRCPath12, Adam S. DuVall13, Xudong Wei, MD, PhD14, Yosr Hicheri, MD15, Zheng GE16, Tomomi Tobai17, Adolfo De la Fuente Burguera, MD18, Irene Sanchez Vadillo19, Ming Yao, MD20, Maher Abdul-Hay, MD21, Marion Strullu22, Stefanie Meyer23, Xu (Sue) Zhu24, Yuyin Liu25, Margaret Wey, PhD26, Marcio Andrade-Campos, MD, PhD27, Hagop Kantarjian, MD28
1 City of Hope Comprehensive Cancer Center, Duarte, California, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 Vall d'Hebron University Hospital, Barcelona, Spain
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 Cedars-Sinai Medical Center, Los Angeles, California, United States
6 Universitätsklinikum Würzburg, Würzburg, Germany
7 IRCCS Bambino Gesù Children’s Hospital, Catholic University of the Sacred Heart, Rome, Italy
8 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South
9 Hospital Clinic, Barcelona, Spain
10 University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
11 The Christie NHS Foundation Trust, Manchester, United Kingdom
12 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
13 University of Chicago Medicine, Chicago, Illinois, United States
14 Henan Cancer Hospital, Zhengzhou, China
15 Institut Paoli-Calmettes, Marseille, France
16 Zhongda Hospital, Southeast University, Nanjing, China
17 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
18 MD Anderson Cancer Center Madrid, Madrid, Spain
19 Hospital Universitario La Paz, Madrid, Spain
20 National Taiwan University Hospital, Taipei, Taiwan
21 NYU Langone Health, New York, New York, United States
22 Hôpital Robert-Debré, Paris, France
23 AstraZeneca, Waltham, Massachusetts, United States
24 AstraZeneca, Waltham, Massachusetts, United States
25 AstraZeneca, Waltham, Massachusetts, United States
26 AstraZeneca, Boston, Massachusetts, United States
27 AstraZeneca, Barcelona, Spain
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Surovatamig, a novel, fully human, IgG4, CD19xCD3 bispecific TCE with low-affinity CD3 binding, has an extended half-life enabling 2-weekly (Q2W) dosing. SYRUS (NCT06137118) is an ongoing Phase 1/2 study evaluating the safety and efficacy of surovatamig monotherapy in pts with R/R B-ALL. Updated safety and efficacy data are presented.

Methods: Eligible pts were aged ≥12 years with R/R CD19+ B-ALL. Surovatamig was administered intravenously in 28-day cycles with triple step-up dosing (SUD) on Cycle (C)1 Days (D)1, 4 and 8, then at target dose (TD) on D15 and Q2W thereafter. Pts with complete response (CR) or CR with partial or incomplete hematologic recovery (CRh/CRi) within 3 cycles could continue until relapse or discontinuation. In Part A, 2 different SUD regimens (0.09/0.27/1.0 mg and 0.27/1.0/2.4 mg) and TDs of 2.4–37.5 mg were evaluated. In Part B, pts were randomized to TDs of 7.2 mg or 15 mg using the selected Part A SUD. Part C expanded the 15 mg TD. Primary outcomes for Parts A, B and C included efficacy, safety and tolerability. Response was assessed by investigators per NCCN criteria. Measurable residual disease (MRD) was assessed by clonoSEQ with a 10-4 cutoff.

Results: As of May 20, 2026, 127 pts with R/R B-ALL had received surovatamig. Median (range) age was 41 (13–84) years; 58% of pts had >50% bone marrow blasts and 19% had extramedullary disease (EMD). Median (range) prior lines of therapy was 3 (1–12); prior blinatumomab: 52%, prior anti-CD19 CAR-T: 35%, prior allogeneic stem cell transplant (alloSCT): 33%. During Part A, the 0.09/0.27/1.0 mg SUD regimen was selected by the Safety Review Committee for further development. Out of 108 pts in Part A, 19 were treated with the non-selected SUD and were not considered for the efficacy analysis. Maximum tolerated dose was not reached.

The efficacy-evaluable population consisted of 89 pts treated at 2.4 mg (n=13), 7.2 mg (n=21), 15 mg (n=43), 25 mg (n=9) and 37.5 mg (n=3). A dose-response relationship was observed. Best overall response (BOR; defined as CR/CRh within 3 cycles) across doses was 53%. BOR per TD was 2.4 mg: 38%, 7.2 mg: 48%, 15 mg: 53%, 25 mg: 78% and 37.5 mg: 67%. In pts with EMD, the BOR at 15 mg was 60%. In pts with prior anti-CD19 therapy, BOR was 48% at 15 mg (n=23) and 80% at 25 mg (n=5). In pts having received prior blinatumomab, BOR was 45% at 15 mg (n=22) and 75% at 25 mg (n=4). In prior anti-CD19 CAR-T-exposed pts, BOR was 42% at 15 mg (n=17) and 100% at 25 mg (n=2). MRD negativity was achieved in 80% (45/56) of MRD-evaluable patients across the trial.

Of 52 responders (CR, n=37; CRh, n=10; CRi, n=5), 12 discontinued treatment to proceed to alloSCT and 1 to consolidation with CAR-T; 14 discontinued due to relapse, 1 due to adverse events (AEs), and 3 due to investigator’s decision; 21 pts continued on treatment. Median (range) treatment duration across doses was 2 (1–20) cycles; 13 and 4 pts received ≥6 and ≥12 cycles, respectively.

At data cutoff, median (range) follow-up for responders was 6.5 (1.0–25.5) months. In the 15 mg group (responders, n=23), median duration of response (mDOR [95% confidence interval]) was 8.1 (5.3–not calculable [NC]) months; mDOR was NC at 25 mg (responders, n=7; median follow-up of 4.6 months).

In the safety-evaluable population (n=124), any-grade (Gr) treatment-related AEs were reported in 95 (77%) pts (Gr ≥3, 33%). Cytokine release syndrome (CRS) was the most common treatment-emergent AE, occurring in 84 (68%) pts (Gr 2, 23%; Gr ≥3, 2%). Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 13 (11%) pts (Gr 2, 6%; Gr ≥3, 2%). With the selected 0.09/0.27/1.0/15 mg schedule, Gr ≥2 CRS occurred in 16/51 (31%) pts and Gr ≥2 ICANS occurred in 3/51 (6%) pts; almost all Gr ≥2 CRS and all ICANS events occurred during C1.

TD-dependent pharmacokinetic exposure was observed with 2.4–37.5 mg TDs. Higher systemic exposure (average concentration during the first 2 cycles) correlated with higher CR/CRh rates. SUD mitigated inflammatory cytokine production, with the strongest cytokine increase seen at first SUD and attenuated cytokine elevations at later SUD and TDs.

Conclusions: These results demonstrate that surovatamig is well tolerated and shows promising efficacy at TDs of ≥15 mg in R/R B-ALL. The SUD regimen taken forward effectively mitigates incidence and severity of CRS and ICANS. These results support further investigation of surovatamig monotherapy in pts with R/R B-ALL.

Ibrahim Aldoss, MD: Amgen - Honoraria; Pfizer - Honoraria; Allotera - Research Funding; Jazz Pharmaceuticals - Research Funding; Novartis - Research Funding; MacroGenics - Research Funding; AbbVie - Research Funding; Autolus - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Syndax Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Acentage - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Adaptive - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony)